Reents Scott T 4

What Happened Scott T. Reents, Chief Financial Officer of AbbVie Inc. (ABBV), was the recipient of multiple performance-based equity awards reported 2026-02-18: 25,062; 8,910; 7,606; and 7,260 shares (all recorded at $0.00) and a derivative award of 21,937 option-share equivalents (also $0.00). The four share awards total 48,838 shares that will be issued to him on February 28, 2026 after the Compensation Committee certified performance goal attainment. The 21,937-unit grant is an employee stock option awarded under AbbVie’s 2013 Incentive Stock Program; it vests in annual increments (7,313 on 2/18/2027; 7,312 on 2/18/2028; 7,312 on 2/18/2029).

Key Details

• Transaction date reported: February 18, 2026; Form 4 filed Feb 20, 2026 (timely within typical two-business-day window).
• Price: $0.00 for all items (these are awards/grants, not purchases).
• Award breakdown: 25,062 (F1), 8,910 (F2), 7,606 (F3), 7,260 (F4) performance-based shares; 21,937 (F5) employee stock option units.
• Total equity units reported: 70,775 (48,838 shares + 21,937 option units).
• Shares to be issued: the awarded shares will be issued on Feb 28, 2026 per footnotes.
• Option vesting schedule (F5): exercisable in annual increments of 7,313 (2/18/2027), 7,312 (2/18/2028), and 7,312 (2/18/2029).
• Footnotes: awards were originally granted on 2/16/2023 (F1,F2), 2/15/2024 (F3), and 2/13/2025 (F4); performance vesting conditions were certified and released on 2/18/2026.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context These entries are awards/vesting events (code A) and an option grant, not open-market purchases or sales. Performance-based awards reflect company-approved achievement of pre-set metrics (EPS, relative TSR, ROE measures noted in footnotes) and will be issued on the stated date; the option is a standard employee grant subject to multi-year vesting. Such compensation filings are routine for executives and do not by themselves indicate a personal buy/sell decision.